Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2008, for Innovative Acquisitions Corp. (not Puma Biotechnology, Inc., as indicated in the metadata). The registrant is a Delaware corporation organized on April 27, 2007, classified as a "shell company" and a "blank check" company. Its sole purpose is to seek a business combination through a merger or acquisition with an operating business. The company has no active operations, no specific business plan, and has generated no revenue since inception.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | As of June 30, 2008 |
|---|---|---|
| Revenue | $0 | N/A |
| Net Loss | $(7,866) | N/A |
| Cash and Cash Equivalents | N/A | $2,291 |
| Total Assets | N/A | $2,291 |
| Total Liabilities | N/A | $500 |
| Stockholders' Equity | N/A | $1,791 |
| Cash Flow from Operations | $(7,366) | N/A |
| Cash Flow from Financing | $8,250 | N/A |
Note: The company reported no debt other than accounts payable of $500. Margins are not applicable due to zero revenue.
Material Changes vs. Prior Period
- Cash Position: Cash increased from $1,407 as of December 31, 2007, to $2,291 as of June 30, 2008, a net increase of $884.
- Liabilities: Accounts payable increased from $0 to $500 during the period.
- Capital Contributions: The company received $8,250 in cash capital contributions from directors during the six months ended June 30, 2008. No new shares were issued for these contributions; they were recorded as additional paid-in capital.
- Accumulated Deficit: The accumulated deficit grew from $(15,093) to $(22,959) due to ongoing operational losses.
Outlook, Risks, and Management Commentary
Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. The company has not generated revenue and is dependent on financial support from shareholders and the ability to obtain equity financing to fund operations and execute its business plan.
Business Plan: The company intends to identify and acquire a target business. It does not restrict potential targets to any specific industry or location. Costs for the next 12 months are expected to include filing fees and expenses related to investigating and consummating an acquisition.
Risks:
- The company is a "blank check" company with no specific business plan.
- Continuation depends entirely on external financing or a successful merger.
- Any target business may be financially unstable or in early development stages.
Unusual Items: The net loss for the period consisted entirely of legal, accounting, audit, and professional service fees related to SEC filings (Form 10-Q and Form 10-KSB).
Investor Verification Checklist
- Company Identity: Verify that the filing is for "Innovative Acquisitions Corp." and not "Puma Biotechnology, Inc." (metadata discrepancy).
- Liquidity Status: Confirm the sufficiency of the $2,291 cash balance to sustain operations for the next 12 months without additional funding.
- Capital Reliance: Assess the commitment of directors to provide further capital contributions, as the company relies on them for survival.
- Merger Progress: Investigate if any specific acquisition targets have been identified or if discussions are ongoing, as the business model relies entirely on a future combination.
- Shell Status: Acknowledge the high risk associated with investing in a shell company with no assets other than cash and no operations.